PDF(Pubmed)
Abstract：
Coronavirus disease 2019 (COVID-19) is often linked to a broad range of opportunistic bacterial and fungal infections. The second wave of the COVID-19 pandemic has witnessed an unprecedented surge in mucormycosis cases, predominantly in India, while the disease remained relatively rare in Europe. The authors describe the case of a 62-year-old female patient admitted to the hospital for consolidation therapy with chemotherapy as a part of the treatment protocol for acute myeloid leukemia. During hospitalization, she was diagnosed with nosocomial COVID-19, which later progressed to respiratory deterioration. COVID-19 with bacterial superinfection was presumed, leading to the initiation of empirical antibiotic therapy. A bronchoscopy was performed several days later due to a lack of improvement, revealing an infection by the Rhizopus microsporus complex. Despite antifungal treatment, the patient experienced an unfavorable clinical course and ultimately died. Given the high index of suspicion required to diagnose pulmonary mucormycosis, which can lead to delays in appropriate treatment and increase the burden of disease, the authors are aiming to enhance its awareness.
摘要：
2019年冠状病毒病（COVID-19）通常与广泛的机会性细菌和真菌感染有关。第二波COVID-19大流行见证了毛霉菌病病例的空前激增，主要在印度，而这种疾病在欧洲仍然相对罕见。作者描述了一名62岁的女性患者入院接受化疗作为急性髓细胞性白血病治疗方案的一部分进行巩固治疗的情况。住院期间,她被诊断为院内感染COVID-19，后来进展为呼吸恶化。推测COVID-19伴有细菌重复感染，导致经验性抗生素治疗的开始。由于缺乏改善，几天后进行了支气管镜检查，揭示了根霉微孢子复合体的感染。尽管有抗真菌治疗,患者经历了不利的临床过程并最终死亡。鉴于诊断肺毛霉菌病需要高度怀疑，这可能导致适当治疗的延误并增加疾病负担，作者旨在增强其意识。
